Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study

Gelijkaardige items

• Screening for Prostate Cancer Starting at Age 50-54. A Population-based Cohort Study
  door: Carlsson, Sigrid, et al.
  Gepubliceerd in: (2016)
• Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
  door: Heijnsdijk, Eveline A M, et al.
  Gepubliceerd in: (2020)
• Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
  door: Kovac, Evan, et al.
  Gepubliceerd in: (2020)
• Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
  door: Assel, Melissa, et al.
  Gepubliceerd in: (2017)
• Twenty year Risk of Prostate Cancer Death by Midlife Prostate specific Antigen and a Panel of Four Kallikrein Markers in a Large Population based Cohort of Healthy Men
  door: Sjoberg, Daniel D., et al.
  Gepubliceerd in: (2018)